S&P 500   4,569.78
DOW   36,204.44
QQQ   386.32
Are penny stocks worth it? Should you invest in penny stocks?
New CBOE “special perk” helps traders target income every weekend (Ad)
Why do tech stocks go down when interest rates rise?
Own Dollar General? Hurry and take this advice before earnings
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Pure Storage stock fumbles for a rare buying opportunity
Black Swan: this small cap surged over 1000% last week
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
AppLovin (APP): Losing its shareholders lovin'?
Snowflake’s bullish tailwind is turning into a gale-force wind
S&P 500   4,569.78
DOW   36,204.44
QQQ   386.32
Are penny stocks worth it? Should you invest in penny stocks?
New CBOE “special perk” helps traders target income every weekend (Ad)
Why do tech stocks go down when interest rates rise?
Own Dollar General? Hurry and take this advice before earnings
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Pure Storage stock fumbles for a rare buying opportunity
Black Swan: this small cap surged over 1000% last week
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
AppLovin (APP): Losing its shareholders lovin'?
Snowflake’s bullish tailwind is turning into a gale-force wind
S&P 500   4,569.78
DOW   36,204.44
QQQ   386.32
Are penny stocks worth it? Should you invest in penny stocks?
New CBOE “special perk” helps traders target income every weekend (Ad)
Why do tech stocks go down when interest rates rise?
Own Dollar General? Hurry and take this advice before earnings
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Pure Storage stock fumbles for a rare buying opportunity
Black Swan: this small cap surged over 1000% last week
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
AppLovin (APP): Losing its shareholders lovin'?
Snowflake’s bullish tailwind is turning into a gale-force wind
S&P 500   4,569.78
DOW   36,204.44
QQQ   386.32
Are penny stocks worth it? Should you invest in penny stocks?
New CBOE “special perk” helps traders target income every weekend (Ad)
Why do tech stocks go down when interest rates rise?
Own Dollar General? Hurry and take this advice before earnings
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Pure Storage stock fumbles for a rare buying opportunity
Black Swan: this small cap surged over 1000% last week
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
AppLovin (APP): Losing its shareholders lovin'?
Snowflake’s bullish tailwind is turning into a gale-force wind

Allakos Stock Price, News & Analysis (NASDAQ:ALLK)

$2.62
+0.34 (+14.91%)
(As of 12/4/2023 ET)
Compare
Today's Range
$2.36
$2.65
50-Day Range
$1.72
$2.50
52-Week Range
$1.48
$8.73
Volume
1.65 million shs
Average Volume
1.00 million shs
Market Capitalization
$229.20 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$11.36

Allakos MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.57 Rating Score
Upside/​Downside
333.5% Upside
$11.36 Price Target
Short Interest
Healthy
3.92% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.86
Upright™ Environmental Score
News Sentiment
0.93mentions of Allakos in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.87) to ($1.84) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.81 out of 5 stars

Medical Sector

51st out of 952 stocks

Pharmaceutical Preparations Industry

11th out of 434 stocks


ALLK stock logo

About Allakos Stock (NASDAQ:ALLK)

Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and/or eosinophilic duodenitis; a Phase II/III study for eosinophilic esophagitis; and a Phase II clinical study to atopic dermatitis and chronic spontaneous urticaria. It is also developing lirentelimab (AK002) for the treatment of mast cell gastrointestinal disease, chronic urticaria, severe allergic conjunctivitis, and indolent systemic mastocytosis; and AK006 to treat allergic and inflammatory diseases. In addition, Allakos Inc. is conducting preclinical studies for AK007, which polarizes tumor-associated myeloid cells and promotes anti-tumor immunity. The company was incorporated in 2012 and is headquartered in San Carlos, California.

ALLK Stock Price History

ALLK Stock News Headlines

Allakos (NASDAQ:ALLK) Stock Rating Reaffirmed by JMP Securities
Trading Experts Call It “The Perfect Tesla Trade”
Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.
Allakos GAAP EPS of -$0.52 misses by $0.06
TD Cowen Reaffirms Their Hold Rating on Allakos (ALLK)
Trading Experts Call It “The Perfect Tesla Trade”
Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.
AlloVir GAAP EPS of -$0.39 beats by $0.01
Why Shares of Allakos Are Up Wednesday
Allakos Appoints Neil Graham to its Board of Directors
Goldman Sachs Sticks to Their Hold Rating for Allakos (ALLK)
Allakos (ALLK) Initiated with a Sell at Barclays
Allakos (ALLK) Earnings Dates & Reports
See More Headlines
Receive ALLK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Allakos and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
5/09/2023
Today
12/04/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
3/04/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ALLK
Fax
N/A
Employees
123
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$11.36
High Stock Price Target
$22.00
Low Stock Price Target
$1.50
Potential Upside/Downside
+333.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.57
Research Coverage
7 Analysts

Profitability

Net Income
$-319,950,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$3.64 per share

Miscellaneous

Free Float
62,921,000
Market Cap
$229.20 million
Optionable
Not Optionable
Beta
0.68
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

  • Dr. Robert Alexander Ph.D. (Age 53)
    CEO & Director
    Comp: $1.46M
  • Dr. Adam L. Tomasi Ph.D. (Age 53)
    President
    Comp: $1.11M
  • Mr. Baird Radford III (Age 53)
    Chief Financial Officer
    Comp: $708.26k
  • Ms. Mary Cromwell Ph.D.
    Chief Technical Officer
  • Dr. Craig Paterson M.D. (Age 58)
    Chief Medical Officer
  • Mr. Alan Chang
    Director of Medical Affairs & Data Analytics














ALLK Stock Analysis - Frequently Asked Questions

Should I buy or sell Allakos stock right now?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Allakos in the last twelve months. There are currently 1 sell rating, 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" ALLK shares.
View ALLK analyst ratings
or view top-rated stocks.

What is Allakos' stock price target for 2024?

7 analysts have issued 1 year price targets for Allakos' stock. Their ALLK share price targets range from $1.50 to $22.00. On average, they anticipate the company's share price to reach $11.36 in the next year. This suggests a possible upside of 333.5% from the stock's current price.
View analysts price targets for ALLK
or view top-rated stocks among Wall Street analysts.

How have ALLK shares performed in 2023?

Allakos' stock was trading at $8.42 at the start of the year. Since then, ALLK stock has decreased by 68.9% and is now trading at $2.62.
View the best growth stocks for 2023 here
.

Are investors shorting Allakos?

Allakos saw a drop in short interest in the month of November. As of November 15th, there was short interest totaling 3,430,000 shares, a drop of 13.2% from the October 31st total of 3,950,000 shares. Based on an average daily volume of 960,600 shares, the short-interest ratio is presently 3.6 days.
View Allakos' Short Interest
.

When is Allakos' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, March 4th 2024.
View our ALLK earnings forecast
.

How were Allakos' earnings last quarter?

Allakos Inc. (NASDAQ:ALLK) posted its quarterly earnings data on Tuesday, May, 9th. The company reported ($0.49) earnings per share for the quarter, meeting the consensus estimate of ($0.49).

What ETF holds Allakos' stock ?

Virtus LifeSci Biotech Clinical Trials ETF holds 22,191 shares of ALLK stock, representing 1.04% of its portfolio.

What other stocks do shareholders of Allakos own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Allakos investors own include AbbVie (ABBV), Advanced Micro Devices (AMD), Pfizer (PFE), Agios Pharmaceuticals (AGIO), Biohaven (BHVN), bluebird bio (BLUE), Eastman Chemical (EMN), Heron Therapeutics (HRTX), TG Therapeutics (TGTX) and Arbutus Biopharma (ABUS).

When did Allakos IPO?

(ALLK) raised $96 million in an IPO on Thursday, July 19th 2018. The company issued 6,000,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs and Jefferies served as the underwriters for the IPO and William Blair was co-manager.

Who are Allakos' major shareholders?

Allakos' stock is owned by many different retail and institutional investors. Top institutional investors include RiverVest Venture Management LLC (5.74%), Redmile Group LLC (4.76%), Blackstone Inc. (4.71%), Vontobel Holding Ltd. (0.89%), Sectoral Asset Management Inc. (0.89%) and Citigroup Inc. (0.52%). Insiders that own company stock include Adam Tomasi, Daniel Janney, Henrik S Md Rasmussen, Paul Edward Walker, Peter A Hudson, Robert Alexander, Robert J More and Steven P James.
View institutional ownership trends
.

How do I buy shares of Allakos?

Shares of ALLK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:ALLK) was last updated on 12/5/2023 by MarketBeat.com Staff

My Account -